Float Short %

1.04

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

0.06

EPS Last/This Y

-1.72

EPS This/Next Y

0.38

Price

0.91

Target Price

Analyst Recom

2.33

Performance Q

-26.61

Relative Volume

1.23

Beta

0.63

Ticker: SPRO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	SPRO	0.9901	0.00	0.00	1939
2024-12-20	SPRO	0.9656	0.00	0.00	1939
2024-12-23	SPRO	0.9213	0.00	0.06	1514
2024-12-24	SPRO	0.94	0.00	0.00	1505
2024-12-26	SPRO	0.9451	0.00	0.00	1509
2024-12-27	SPRO	1.03	0.00	0.00	1509
2024-12-30	SPRO	1.02	0.00	0.00	1509
2024-12-31	SPRO	1.03	0.00	0.00	1519
2025-01-02	SPRO	1.07	0.00	0.00	1520
2025-01-03	SPRO	1.1	0.00	0.00	1531
2025-01-06	SPRO	1.08	0.00	0.00	1531
2025-01-07	SPRO	1.055	0.00	0.00	1531
2025-01-08	SPRO	1	0.00	0.00	1531
2025-01-09	SPRO	1	0.00	0.00	1531
2025-01-10	SPRO	0.9774	0.00	999.99	1535
2025-01-13	SPRO	0.9414	0.01	999.99	1550
2025-01-14	SPRO	0.9653	0.01	999.99	1550
2025-01-15	SPRO	0.89	0.01	999.99	1553
2025-01-16	SPRO	0.852	0.01	999.99	1553
2025-01-17	SPRO	0.906	0.05	0.00	1613
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	SPRO	0.99	-142.4	-	-1.29
2024-12-20	SPRO	0.96	-142.4	-	-1.29
2024-12-23	SPRO	0.92	-142.4	-	-1.29
2024-12-24	SPRO	0.94	-142.4	-	-1.29
2024-12-26	SPRO	0.94	-142.4	-	-1.29
2024-12-27	SPRO	1.03	-142.4	-	-1.29
2024-12-30	SPRO	1.02	-142.4	-	-1.29
2024-12-31	SPRO	1.03	-142.4	-	-1.29
2025-01-02	SPRO	1.08	-142.4	-	-1.29
2025-01-03	SPRO	1.10	-142.4	-	-1.29
2025-01-06	SPRO	1.08	-142.4	-	-1.29
2025-01-07	SPRO	1.05	-142.4	-	-1.29
2025-01-08	SPRO	1.00	-142.4	-	-1.29
2025-01-09	SPRO	1.00	-142.4	-	-1.29
2025-01-10	SPRO	0.98	-142.4	-	-1.29
2025-01-13	SPRO	0.95	-142.4	-	-1.29
2025-01-14	SPRO	0.97	-142.4	-	-1.29
2025-01-15	SPRO	0.90	-142.4	-	-1.29
2025-01-16	SPRO	0.84	-142.4	-	-1.29
2025-01-17	SPRO	0.91	-142.4	-	-1.29
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	SPRO	-0.56	-15.31	1.25
2024-12-20	SPRO	-0.56	-15.31	1.25
2024-12-23	SPRO	-0.58	-15.31	1.25
2024-12-24	SPRO	-0.58	-15.31	1.25
2024-12-26	SPRO	-0.55	-15.31	1.14
2024-12-27	SPRO	-0.56	-15.31	1.14
2024-12-30	SPRO	-0.51	-16.48	1.14
2024-12-31	SPRO	-0.51	-16.48	1.14
2025-01-02	SPRO	-0.55	-16.48	1.14
2025-01-03	SPRO	-0.56	-16.48	1.14
2025-01-06	SPRO	-0.55	-15.31	1.14
2025-01-07	SPRO	-0.55	-15.31	1.14
2025-01-08	SPRO	-0.56	-15.31	1.14
2025-01-09	SPRO	-0.56	-15.31	1.14
2025-01-10	SPRO	-0.56	-15.31	1.14
2025-01-13	SPRO	-0.56	-15.31	1.04
2025-01-14	SPRO	-0.56	-15.31	1.04
2025-01-15	SPRO	-0.56	-15.31	1.04
2025-01-16	SPRO	-0.56	-15.31	1.04
2025-01-17	SPRO	-0.56	-15.31	1.04
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.32

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

-0.27

Insider Transactions

-0.56

Institutional Transactions

-15.31

Beta

0.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

96.2

Max Drawdown 5-Year %

-96.9

Target Price

P/E

11.46

Forward P/E

PEG

P/S

0.55

P/B

0.75

P/Free Cash Flow

EPS

0.08

Average EPS Est. Cur. Y

-1.29

EPS Next Y. (Est.)

-0.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.91

Relative Volume

1.23

Return on Equity vs Sector %

-13.7

Return on Equity vs Industry %

-1.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.3

EBIT Estimation

Spero Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 46

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today

news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance

stock history SPRO – Spero Therapeutics, Inc. invest stock market

stock prices SPRO premarket after hours

ticker SPRO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SPRO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y